Business Context and Reporting Period
This Form 8-K Current Report was filed by NewAmsterdam Pharma Company N.V. on August 10, 2026. The filing discloses a change in executive management, specifically the appointment of a new principal accounting officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensation arrangements rather than financial performance.
Material Changes
The primary material change is the appointment of Robert W. Gunning as the Company's principal accounting officer, effective August 10, 2026. He succeeds Louise Kooij, whose departure is effective August 31, 2026. Mr. Gunning initially joined as Vice President, Controller.
Management Commentary and Compensation
Mr. Gunning's compensation package, outlined in an offer letter dated July 24, 2026, includes:
- Base Salary: $375,000 per year.
- Performance Bonus: Target of 30% of base salary, subject to Board discretion and prorated for the first partial year.
- Equity Awards: 3,200 restricted stock units (RSUs) and stock options to purchase 14,000 ordinary shares under the 2024 Inducement Plan.
Mr. Gunning brings prior experience from Altimmune, Inc., Y-mAbs Therapeutics, Inc., Excision Biotherapeutics, Inc., and Advanced Accelerator Applications USA, Inc. The filing states there are no undisclosed family relationships or material interests in transactions requiring Item 404(a) disclosure.
Investor Verification Checklist
- Verify the effective date of Louise Kooij's departure (August 31, 2026) and the transition plan for the accounting function.
- Review the full Offer Letter for Robert W. Gunning, which is expected to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026.
- Confirm the vesting schedules and exercise terms for the 3,200 RSUs and 14,000 stock options granted under the 2024 Inducement Plan.
- Monitor future filings for any impact on the Company's internal controls over financial reporting due to the leadership change.